Source: Journal of Clinical Oncology. Unidade: FM
Subjects: PLACEBOS (ADMINISTRAÇÃO), ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), MÉTODO DUPLO-CEGO, METÁSTASE NEOPLÁSICA, NEOPLASIAS COLORRETAIS (SECUNDÁRIO;TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOFF, Paulo M. et al. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, v. 30, n. 29, p. 3596-3603, 2012Tradução . . Disponível em: https://doi.org/10.1200/JCO.2012.42.6031. Acesso em: 17 nov. 2024.APA
Hoff, P. M., Hochhaus, A., Pestalozzi, B. C., Tebbutt, N. C., Li, J., Kim, T. W., et al. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, 30( 29), 3596-3603. doi:10.1200/JCO.2012.42.6031NLM
Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, Eyll B van, Pike L, Fielding A, Robertson JD, Saunders MP. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) [Internet]. Journal of Clinical Oncology. 2012 ; 30( 29): 3596-3603.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1200/JCO.2012.42.6031Vancouver
Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, Eyll B van, Pike L, Fielding A, Robertson JD, Saunders MP. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) [Internet]. Journal of Clinical Oncology. 2012 ; 30( 29): 3596-3603.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1200/JCO.2012.42.6031
